Novel biomarkers and the natriuretic peptide-cGMP signal pathway in the Cardiooncology

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036029

Enrollment

300

Registered

2025-01-29

Start date

2025-07-15

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50.9

Interventions

Group 1: Women with early breast cancer scheduled for chemotherapy that include therapy regimes with cardiotoxic potential.

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Informed consent Age =18 years Women with early breast cancer scheduled for chemotherapy that include cardiotoxic agents

Exclusion criteria

Exclusion criteria: Severe renal insufficiency (GFR2xULN (250 pg/ml) life expectancy of =12 weeks

Design outcomes

Primary

Measure	Time frame
Reduction of the LV-EF (10 absolute point reduction or below 50%) or the global longitudinal strain by 10% or death in the first 12 months	—

Secondary

Measure	Time frame
Elevation of cardiac biomarkers (NT-proBNP, high sensitive TroponinT) Change of natriuretic peptides and/or cGMP levels Change of other biomarker levels Clinical symptoms of heart failure (NYHA classification) Occurrence of diastolic heart failure Occurrence of ventricular or supraventricular arrhythmias	—

Countries

Germany

Contacts

Public ContactIstvan Bojti

Universitätsklinikum Freiburg - Universitäts-Herzzentrum Freiburg-Bad Krozingen

istvan.bojti@uniklinik-freiburg.de+4976127034010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026